These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31401409)

  • 1. Sarcopenia and AFP Level in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation.
    Binay Safer V; Eyigör S
    J Surg Res; 2019 Nov; 243():574-575. PubMed ID: 31401409
    [No Abstract]   [Full Text] [Related]  

  • 2. Sarcopenia and AFP Level in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation: In Response.
    Acosta LF; Gedaly R; Lee JT
    J Surg Res; 2019 Nov; 243():576-577. PubMed ID: 31401410
    [No Abstract]   [Full Text] [Related]  

  • 3. Preoperative Alfa-Fetoprotein and Fibrinogen Predict Hepatocellular Carcinoma Recurrence After Liver Transplantation Regardless of the Milan Criteria: Model Development with External Validation.
    Jiang N; Zeng KN; Dou KF; Lv Y; Zhou J; Li HB; Tang JX; Li JJ; Wang GY; Yi SH; Yi HM; Li H; Chen GH; Yang Y
    Cell Physiol Biochem; 2018; 48(1):317-327. PubMed ID: 30016765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma.
    Berry K; Ioannou GN
    Liver Transpl; 2013 Jun; 19(6):634-45. PubMed ID: 23536495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AFP in OLT for HCC?: Another shadow on the cave wall: Comment on "Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer".
    Cameron AM
    Arch Surg; 2011 Jan; 146(1):33-4. PubMed ID: 21305708
    [No Abstract]   [Full Text] [Related]  

  • 6. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
    Mazzaferro V; Sposito C; Zhou J; Pinna AD; De Carlis L; Fan J; Cescon M; Di Sandro S; Yi-Feng H; Lauterio A; Bongini M; Cucchetti A
    Gastroenterology; 2018 Jan; 154(1):128-139. PubMed ID: 28989060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma.
    Shindoh J; Sugawara Y; Nagata R; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Tanaka T; Kokudo N
    Transpl Int; 2014 Apr; 27(4):391-8. PubMed ID: 24472068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peri-Transplant Change in AFP Level: a Useful Predictor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation.
    Yoo T; Lee KW; Yi NJ; Choi YR; Kim H; Suh SW; Jeong JH; Lee JM; Suh KS
    J Korean Med Sci; 2016 Jul; 31(7):1049-54. PubMed ID: 27366001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.
    Yaprak O; Akyildiz M; Dayangac M; Demirbas BT; Guler N; Dogusoy GB; Yuzer Y; Tokat Y
    Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):256-61. PubMed ID: 22672818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of alpha-fetoprotein mRNA level on the tumor cell hematogenous spread of patients with hepatocellular carcinoma undergoing orthotopic liver transplantation.
    Wang YL; Li G; Wu D; Liu YW; Yao Z
    Transplant Proc; 2007; 39(1):166-8. PubMed ID: 17275497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer.
    Mailey B; Artinyan A; Khalili J; Denitz J; Sanchez-Luege N; Sun CL; Bhatia S; Nissen N; Colquhoun SD; Kim J
    Arch Surg; 2011 Jan; 146(1):26-33. PubMed ID: 21242442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-fetoprotein in liver transplantation for hepatocellular carcinoma: The lower, the better.
    Mazzaferro V; Droz Dit Busset M; Bhoori S
    Hepatology; 2018 Aug; 68(2):775-777. PubMed ID: 29425402
    [No Abstract]   [Full Text] [Related]  

  • 14. Promise and Pitfalls of Using α-Fetoprotein in Liver Transplantation Allocation for Hepatocellular Carcinoma.
    Schlansky B; Orloff SL
    JAMA Surg; 2017 Jan; 152(1):64-65. PubMed ID: 27706491
    [No Abstract]   [Full Text] [Related]  

  • 15. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
    Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
    Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of alfa fetoprotein to traditional criteria for hepatocellular carcinoma improves selection accuracy in liver transplantation.
    Sternby Eilard M; Holmberg E; Naredi P; Söderdahl G; Rizell M
    Scand J Gastroenterol; 2018 Aug; 53(8):976-983. PubMed ID: 30169974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Pre-transplantation Serum Alpha-Fetoprotein Levels in Hepatocellular Carcinoma Recurrence.
    Montalvá EM; Cantos M; Boscà A; Rubín A; Vinaixa C; Granero P; Maupoey J; López-Andújar R
    Transplant Proc; 2016 Nov; 48(9):2966-2968. PubMed ID: 27932120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter to Editor: Locoregional Therapy Before Liver Transplantation for Hepatocellular Carcinoma.
    Jiang N; Li X; Xing YF; Qiao YD; Chen J
    Hepatology; 2019 Oct; 70(4):1490-1491. PubMed ID: 31090941
    [No Abstract]   [Full Text] [Related]  

  • 19. α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation.
    Zhang Q; Shang L; Zang Y; Chen X; Zhang L; Wang Y; Wang L; Liu Y; Mao S; Shen Z
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):544-52. PubMed ID: 24614696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.
    Kemmer N; Neff G; Kaiser T; Zacharias V; Thomas M; Tevar A; Satwah S; Shukla R; Buell J
    Liver Transpl; 2006 Oct; 12(10):1519-22. PubMed ID: 17004260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.